natgillin/translations-raw huggingface dataset:
The infuser for alcoholic beverages according to claim 7, characterized by the fact that the ethyl alcohol tank (1) and/or the water tank (1') incorporate automatic shut-off valves. The infuser for alcoholic beverages according to claim 7, characterized by the fact that the ethyl alcohol tank (1) and/or the water tank (1') incorporate level sensors. 
Infuzor za alkoholna pića u skladu s patentnim zahtjevom 1 ili 2, naznačen time što spremnik etil-alkohola (1), spremnik vode (1?) ili i spremnik etil-alkohola (1) i spremnik vode (1*) sadrže automatske zatvaračke ventile. Infuzor u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što su senzori razine infracrvene naprave.
to afford Compound G of the formula, which is optionally crystallized to improve quality, and 
Spoj F da se dobije Spoj G formule, koji po izboru može kristalizirati radi poboljšanja kvalitete, 1
A polymorph for use as claimed in claim 12, wherein the leukemia is selected from childhood leukemia, hairy-cell leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia. 
Polimorf za uporabu prema patentnom zahtjevu 20, naznačen time što je leukemija odabrana od leukemije dečjeg uzrasta, leukemije vlasastih stanica, akutne limfocitne leukemije, akutne mijelocitne leukemije, kronične limfocitne leukemije, kronične mijelocitne leukemije, kronične mijeloične leukemije i leukemije mastocita.
These influences are associated with reduced rate of longitudinal nail growth, thinning of the nail plate and accentuation of longitudinal ridges. 
Ovi utjecaji povezani su sa smanjenom brzinom longitudinalnog rasta nokta, stanjivanjem ploče nokta i naglašavanjem longitudinalnih grebena.
A packaging according to any of the preceding claims, wherein the inner part comprises recesses on each side having a shape and depth substantially corresponding to the shape and thickness of the first and second part, respectively. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što unutarnji dio sadržava udubljenje na svakoj strani koje ima oblik i dubinu koja približno odgovara obliku i debljini prvog odnosno drugog dijela.
The method of claim 1, wherein the profiling takes place before the pressing. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, što faza profiliranja prethodi fazi prešanja.
One class of preferred hardenable resins comprises materials having free radically active functional groups and includes monomers, oligomers and polymers having one or more ethylenically unsaturated groups. 
Jedna klasa preferiranih smola koje očvršćuju sadrži materijale koji imaju aktivne funkcionalne skupine sa slobodnim radikalima 1 obuhvaćaju monomere, oligomere i polimere koji imaju jednu ili više nezasićenih skupina poput etilena.
Use of a compound for claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of the compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof for the treatment of pain or diarrhea. 
Uporaba spoja prema zahljevu 1 ili 2 ili njegove farmaceulski prihvatljive soli naznačena time da je za dobivanje lijeka za stimuliranje funkcije opioidnog-receptora u stanici koje se sastoji od dovođenja u kontakt stanice koja može eksprimirati opioidni receptor sa učinkovitom količinom spoja prema zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli kod liječenja boli ili proljeva.
The oligomer according to embodiment 1 or 2, wherein the internucleoside linkages other than phosphodiester are sulphur containing internucleoside linkages, such as phosphorothioate, phosphorodithioate and boranophosphate, such as phosphorothioate. 
Oligomerni spoj prema patentnom zahtjevu 1, naznačen time, da su poveznice među nukleoizidima osim fosfodiestera, odabrane iz skupine koja se sastoji od fosforotioata, fosforoditioata i boranofosfata.
The compound according to claim 1, having the formula VI: or a tautomer, enantiomer or salt thereof, wherein: 
Spoj u skladu s patentnim zahtjevom 1, s formulom VI: [image], ili njegov tautomer, enantiomer ili sol, naznačen time što:
carbonyl scavenger compound selected from free acid forms, salts, carboxylic acid esters derivatives of a compound of formula (II) H2N-(CH2)m-(C6H4)-COOH (II) 
6) spoj za čišćenje karbonila odabran od slobodnih oblika kiseline, soli, derivata estera karboksilne kiseline spoja prema formuli (II) HoN-(CHo)n-(C6H4)-COOH
The invention will now be described in further detail in the following numbered paragraphs: An isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising: 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) i makaki CD38 (SEQ ID NO:2) koje sadrži: a) = varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:9; b) varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10; 1 c) - kovalentno vezan dio lijeka.
A developer supply container (1) according to Claim 1, wherein said drive converting portion (2d, 3b) converts the rotational force received by said driving force receiving portion (2a) to the force for operating said pump portion that reciprocates said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 1, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje nastalu vrtnjom navedenog zupčanika (2a) u silu za rad navedenog crpnog dijela kako bi se promijenilo djelovanje navedenog crpnog dijela (2b).
Recoil damper system according to claim 1, in which said mobile interface (50), and particularly said shafts (53), are made in order to exhibit limited friction so that they do not jam and in order to facilitate sliding in the guides (23). 
Sustav za prigušivanje trzanja u skladu s patentnim zahtjevom 1, u kojemu su navedeni pokretni međusklop (50) 1 naročito navedene osovine (53) načinjeni tako da mogu imati ograničeno trenje pa da ne prave smetnje i da olakšaju klizanje u vodilicama (23).
at least 18% of the population express on their surfaces detectable levels of CD363 (Sphingosine-1-phosphate receptor 1), 
(v) najmanje 18 % stanica u populaciji na svojoj površini izražava uočljive razine CD363 (sfingozin-1-fosfat receptor 1),
Figure 2 is a perspective view of the portion of shoe of Figure 1; 
Slika 2 je perspektivni prikaz dijela cipele iz Slike 1;
A compound of or pharmaceutically acceptable salt, hydrate, or solvate thereof for use in the treatment of a substance withdrawal disorder. 
Spoj prema zahtjevu 1 ili zahtjevu 2 naznačen time da je u obliku farmaceutski prihvatljive soli.
Column temperature: 25° C. 
Temperatura stupca: 25 *C
The present invention also contemplates treatment regimens in which an IL-17 antagonist is used in combination with an IL-23 antagonist. 
. Uporaba u skladu sa zahtjevom 89, naznačena time, da antagonist je IL-23 antagonist.
The compound of Formula I as defined in any one of claims 1-4, wherein the compound and the CDA substrate drug are administered in a single unit dosage form. 
Spoj prema bilo kojem od zahtjeva 14-24 za uporabu u postupku liječenja raka, gdje se spoj i lijek koji je supstrat za CDA primjenjuju u jednom dozirnom obliku.
The compound 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine, or a pharmaceutically acceptable salt thereof. 
-(trifluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amin, ili njegova farmaceutski prihvatljiva sol.
The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent. 
Aktivni sastojak može se otopiti ili suspendirati u farmaceutski prihvatljivoj podlozi, poput sterilne vode, sterilnog organskog otapala, ili smjese sterilne vode sa sterilnim organskim otapalom.
This invention relates to the use of dihydrotetrabenazine in the prophylaxis or treatment of a psychosis. 
Ovaj izum se odnosi na uporabu dihidrotetrabenazina u proizvodnji lijeka za profilaksu ili liječenje psihoze.
The resulting yellow solution was stirred overnight. 
Dobivenu žutu otopinu miješa se preko noći.
a suction tube adapted for conveying material from the crusher to the separator, and a second conveyor adapted for conveying the portion A from the separator to said de-waxing container A processing plant according to claim 9, wherein said second conveyor are arranged in a dust proof tube, comprising an inlet and an outlet opening arranged at each end of said dust proof tube. 
cijev za odsisavanje, podešenu za transport materijala iz mrvilice u separator, te d. - drugi transporter, podešen za transport dijela A iz separatora u navedeni spremnik za odvoštavanje. Postrojenje za obradu u skladu s patentnim zahtjevom 9, naznačeno time što se navedeni drugi transporter nalazi u cijevi nepropusnoj za prašinu, koja ima ulazni i izlazni otvor, koji se nalaze na svakom kraju navedene cijevi nepropusne za prašinu.
The pharmaceutical composition for use of claim 7, wherein each of the initial dose and the secondary doses of the pharmaceutical composition comprise 75 mg to 600 mg of the antibody or antigen-binding fragment, and/or wherein the pharmaceutical composition is administered to the subject systemically, subcutaneously, intravenously, or intranasally. 
Farmaceutski pripravak za uporabu prema zahtjevu 7, naznačen time što svaka od početne doze i sekundarne doze farmaceutskog pripravka sadrži 75 mg do 600 mg protutijela ili njegovog ulomka koji veže antigen, i/ili pri čemu se farmaceutski pripravak daje subjektu sistemski, potkožno, intravenski ili intranazalno.
The polypeptide of claim 7, wherein the poly(bromomethyl)benzene is selected from the group consisting of 1,2-bis(bromomethyl)benzene, 1,3-bis(bromomethyl)benzene and 1,4-bis(bromomethyl)benzene. 
Polipeptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni polipeptid izabran iz grupe koja se sastoji od SEQ ID NOs 177, 184 i 194.
providing the blood bags with coded-identification means which also comprise data concerning the blood contained in the same bag; 
- < opskrbljivanje vrećica krvi sa sredstvom koje ima kodiranu identifikaciju koja također sadržava podatke koji seo odnose na krv koja je sadržana u toj vrećici;
The method of claim 1, wherein said total amount of said produced TNFR-Ig is at least 2-fold higher that the amount of TNFR-Ig produced under otherwise identical conditions in otherwise identical medium that lacks said medium characteristic. 
Postupak prema Zahtjevu 1, gdje je spomenuta ukupna količina dobivenog TNFR-Fc najmanje 2-puta veća nego količina dobivenog TNFR-Fc pod inače identičnim uvjetima, u inače identičnom mediju, kojem nedostaju spomenute karakteristike medija.
A method for assembling a closure capsule according to any one of claims 1 to 5, characterized in that it comprises the steps of: 
Metoda za sklapanje kapsule za zatvaranje prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time što ona obuhvaća korake:
Exhaust system (1) according one of the preceding claims, characterized in that the control unit (11) is adapted to control the valve member (93, 93b, 95, 97) as well as the valve device (13, 52, 72) further according to the following setting: 
Ispušni sustav (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time što je kontrolna jedinica (11) prilagođena za upravljanje elementom ventila (9) kao i uređajem ventila (13) prema sljedećem postavu:
a.) an effective amount of crystalline solifenacin or its pharmaceutically acceptable salt, 
učinkovitu količinu kristala solifenacina ili njegove farmaceutski prihvatljive soli;
Title compound (m=80g) was obtained in a 89% yield. 
Spoj iz naslova (m = 80 g) dobije se s prinosom od 89 %.
A process for the preparation of an adhesive hygienizing composition for the cleaning and/or disinfecting and/or perfuming of sanitary fixtures, said composition being directly applied to the sanitary fixture, and comprising 
Postupak pripreme adhezivnog higijenskog sredstva za čišćenje i/ili dezinfekciju i/ili parfimiranje sanitarija, koje sredstvo ima maksimalni sadržaj vode od 2.5%, i koje sadrži:
Method according to claim 32, wherein said codes generated by said code generator are not stored. 
Metoda u skladu s patentnim zahtjevom 33, naznačena time, da se kodovi generirani generatorom kodova (106) ne pohranjuju.
The method according to any of Paragraphs 2 to 44, wherein the HIF-1a 4-prolyl hydroxylase inhibitor is a salt comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
Within the context of the present invention, it is also possible to provide an immobile phase, e.g. in the form of a cake or layer, comprising the surface-reacted natural calcium carbonate, the water to be purified running through said immobile phase. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je voda koju treba pročistiti izabrana od industrijske otpadne vode, vode za piće, urbane otpadne vode, otpadne vode iz pivovara ili drugih industrija pića, ili vode u industriji papira.
The immunogenic composition of claims 1-16 or the vaccine of claim 17 for use according to claim 19 wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans, exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans, meningitis and/or bacteraemia of infant humans, otitis media of infant humans or pneumonia and/or conjunctivitis of infant humans. 
Upotreba u skladu s patentnim zahtjevom 16, naznačena time što je bolest bilo koja od ili obje od pneumonija ili invazivna pneumokokna bolesti (IPD) kod starijih ljudi, pogoršanje kronične opstruktivne plućne bolesti (COPD) kod starijih ljudi, meningitis i/ili bakteriemija kod ljudske dojenčadi, upala srednjeg uha kod ljudske dojenčadi ili pneumonija ifili konjunktivitis kod ljudske dojenčadi.
A package including a topical composition as defined in claim 4, said package comprising a container and instructions for use of the topical composition for treating or preventing the symptoms of rosacea. 
Topička kompozicija za uporabu prema patentnom zahtjevu 3, naznačeno time da je navedena kompozicija uključena u pakiranje, navedeno pakiranje sadrži spremnik i upute za uporabu topičke kompozicije za liječenje rosaceom induciranog crvenila.
The kit-of parts for use according to claim 15 or 16 wherein said cyclophosphamide is administered to said patient at least 24 hours prior to the administration of the antibody or PD-1 binding fragment thereof. 
Pripravak za uporabu prema zahtjevu 27 naznačen time da je za uporabu u postupku prema zahtjevu 27 pri čemu se navedeni ciklofosfamid daje navedenom pacijentu najmanje 24 sata prije davanja fuzijskog proteina.
0.5-5% (w/w) in addition to flupentixol or a pharmaceutically acceptable salt thereof corresponding to 0.1-20 mg free base and melitracen or a pharmaceutically acceptable salt thereof corresponding to 1-30 mg free base. 
0.5-5% (w/w) dodatno uz flupentiksol ili njegovu farmaceutski prihvatljivu sol koja odgovara 0.1-20 mg slobodne baze i melitracen ili njegovu farmaceutski prihvatljivu sol koja odgovara 1-30 mg slobodne baze.
Iota-carrageenan for use as claimed in claim 13, wherein iota-carrageenan is present as an anti-paramyxoviral or anti-human influenza A virus effective adjuvant together with one or more non-carrageenan physiologically active substances that are typically applied in the prophylaxis or therapy of infectious and/or inflammatory diseases, allergies and/or conditions of an impaired or suppressed immune system. 
Jota-karagenan namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je jota-karagenan prisutan kao adjuvans djelotvoran protiv paramiksovirusa ili protiv virusa ljudske influence A, uz jednu ili više fiziološki aktivnih tvari koje nisu karagenani, koje se obično upotrebljava u profilaksi ili terapiji infektivnih i/ili upalnih bolesti, alergija i/ili stanja oštećenog ili suprimiranog imunološkog sustava.
The method for improving the hydrophobic properties of a fiber cement product, comprises first the step 200 of providing a green fiber cement product, preferably a plate. 
HR P20190976 T1 PATENTNI ZAHTJEVI Postupak za poboljšanje hidrofobnih svojstva vlaknastog cementnog proizvoda, naznačen time što navedeni postupak sadrži korake
a coding region encoding a therapeutically active protein or peptide, an adjuvant protein, an antigen, a tumour antigen, a pathogenic antigen, an animal antigen, a viral antigen, a protozoal antigen, a bacterial antigen, an allergenic antigen, an autoimmune antigen, an allergen, an antibody, an immunostimulatory protein or peptide, or an antigen-specific T-cell receptor; provided that the coding region does not code for histone proteins, reporter proteins selected from EGFP and Luciferase and marker or selection proteins selected from alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase, at least one histone stem-loop, and 
Sekvenca nukleinske kiselina koja sadrži ili kodira a) kodirajuće područje koje kodira terapeutski aktivni protein ili peptid, adjuvantni protein, antigen, tumorski antigen, patogeni antigen, životinjski antigen, virusni antigen, protozoalni antigen, bakterijski antigen, alergeni antigen, autoimuni antigen, alergen, protutijelo, imunostimulatorni protein ili peptid, ili antigen-specifični receptor T-stanica; pod uvjetom da kodirajuće područje ne kodira histonske proteine, reporterske proteine odabrane od EGFP i Luciferaze i označavajuće ili selekcijske proteine odabrane od alfa-Globina, galaktokinaze i ksantin:gvanin fosforibozil transferaze, b) barem jedan histon peteljka-omča, i
said insulin is bolus insulin, basal insulin, or an analogue thereof. 
navedeni inzulin je bolus inzulin, bazni inzulin ili njegov analog.
Figure 11 is a schematic diagram of an alternative arrangement for connecting the receiver to an acoustic transducer, wherein the transducer is controlled by an external relay. 
Slika 11 je shematski dijagram alternativnog razmještaja za spajanje prijemnika na akustički davač, pri čemu se davač upravlja pomoću vanjskog sklopa.
A process to make fusidic acid cream as claimed in claim 9 further wherein a humectant is added to the mixing vessel of step a in claim 9 said humectant being selected from a group comprising Glycerin, Sorbitol, Propylene glycol and the like, either singly or any combination thereof, from about 5% (w/w) to 40% (w/w), preferably 30% (w/w), more preferably 25% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema patentnom zahtjevu 9, naznačen time, da so nadalje ovlaživač dodaje u posudu za miješanje iz stupnja a u patentnom zahtjevu 9, a navedeni ovlaživač se odabire iz skupine koja sadrži glicerin, sorbitol, propilenglikol i slične, ili pojedinačno ili bilo koju njihovu kombinaciju, u količini od oko 5% (tež.) do 40% (tež.), prvenstveno 30% (tež.), pogodnije 25% (tež.).
A pharmaceutical dosage form comprising oxycodone hydrochloride and less than 25 ppm 14-hydroxycodeinone, and a pharmaceutically acceptable excipient. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
The transdermal delivery device of claim 1, where the matrix comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubberlike synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je sloj koji sadrži lijek matrični sloj, i da matrica poželjno sadrži materijal odabran iz skupine koja se sastoji od polietilena, polipropilena, etilen/propilen kopolimera, etilen/etilakrilat kopolimera, etilenvinil acetatnih kopolimera, silikona, gume, sintetičkih homo-, ko- ili blok polimera sličnih gumi, poliakrilinih estera i njihovih kopolimera, poliuretana, poliizobutilena, kloriranih polietilena, polivinilklorida, vinil klorid-vinil acetat kopolimera, polimera polimetakrilata (hidrogel), poliviniliden klorida, poli(etilen tereftalata), etilen-vinil alkohol kopolimera, etilen-viniloksietanol kopolimera, silikona (npr. silikon kopolimera kao što su polisiloksan-polimetakrilat kopolimera), celuloznih polimera (npr. etil celuloze i estera celuloze), polikarbonata, politetrafluorocetilena i njihovih smjesa. .
The method of claim 1 wherein the compound is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
In an additional embodiment, Z is imidazo[1,2-a]pyridin-2-yl substituted with up to 2 substituents independently selected from C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano. 
Spoj prema bilo kojem od zahtjeva 1-10, naznačen time da je Z supstituiran s najviše tri supstituenta nezavisno odabrana iz skupine koju sačinjavaju C;-, alkil, C,4 alkoksi, C2-Cy cikloalkil, C3-C4 cikloalkiloksi, halogen, alkilsulfonil i cijano.
downstream of these switching means (80), a multiplier circuit for scaling the estimated offset as a function of the ratio between the said first (f1) and second (f2) transmission operating frequency. 
- < umnožavajući sklop za određivanje veličine očekivanog odašiljanja kao funkcije raspona između spomenute prve (f;) i druge (f2) operativne frekvencije emitiranja, postavljen niže u strujnom poretku od ovog sklopa za zamjenu (80).
A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in claim 1 . 
Kompozit naznačen time da sadrži farmaceutski prihvatljiv nosač i, kao aktivni sastojak, terapeutski djelotvornu količinu spoja kako je definirano u bilo kojem od patentnih zahtjeva 1 do 12.
A polypeptide of HDM201 ESVKYVQSNGGAI (SEQ ID 80) or a variant thereof as defined in claim 1. 
Polipeptid, naznačen time, što je od HDM203B DLRQMRTVTPIRMQGGSGS, ili njegove varijante kao što je definirano u zahtjevu 1 (ii) ili (iii).
Generation of 158RHA DNA sequence-Generation of 158RHAss DNA sequence 
Generiranje 158RHA DNK sekvenca - Generiranje 158RHAss DNK sekvenca
optionally providing, on the bottom (12), a leveling layer (13) of sand, clay or other similar and suitable material, 
- opcionalno osiguravanje, na dnu (12), nivelirajućeg sloja (13) pijeska, gline ili drugog sličnog prikladnog materijala,
a bit deinterleaver configured to bit-deinterleave the multiplexed Layer 1 signaling data and at least one LDPC parity bit; 
sredstvo za zatvaranje proboja (r303a) podešeno za zatvaranje proboja barem jednog LDPC paritetnog bita;
The compound for use according to claim 7 or claim 8 for use in a method of prophylaxis or treatment of cancer in a patient selected from: 
Spoj za upotrebu prema patentnom zahtjevu 13, naznačen time da je u postupku profilakse ili tretmana raka kod pacijenta: